Table 1.
Current data on the treatment of PM from CRC by either systemic therapy alone or in combination with locoregional treatment. It is critical to highlight that the amount of disease in the peritoneum or the chemotherapy regimen differed among the studies. (amount of disease: +++ extensive load of PM, ++ moderate load, + limited load, NA: not available).
| PM—CRC Outcome after Different Treatment Approaches | |||||
|---|---|---|---|---|---|
| mOS (Months) | |||||
| CRS/HIPEC | Systemic Chemotherapy | PIPAC | Amount of Disease | Used Drug | |
| Vervaal V. et al., 2003 [60] | 22.2 | 12.6 | - | +++ | 5FU |
| Elias D. et al., 2009 [58] | 67.7 | 23.9 | - | ++ | FOLFOX/FOLFIRI |
| Franko J. et al., 2016 [5] | 16.3 | - | - | NA | FOLFOX/FOLFIRI +/−ab |
| Cremolini Ch. et al., 2020 [75] | - | 28.9 | - | NA | FOLFOXIRI |
| Quenet F. et al., 2021 [59] | 41 | - | - | ++ | FOLFOX/FOLFIRI |
| Breuer E. et al., 2021 [4] | 51 | - | - | ++ | FOLFOX/FOLFIRI |
| Demtröder C. et al., 2015 [76] | - | - | 15.7 | +++ | FOLFOX/FOLFIRI +/−ab |
| Goére D. et al., 2020 [77] | mOS not reached during 50.8 months of follow-up | - | + | FOLFOX/XELOX | |